KRAS Amplification in Metastatic Colon Cancer is Associated with a History of Inflammatory Bowel Disease and May Confer Resistance to anti-EGFR Therapy

Mutations in RAS occur in 30–50% of metastatic colorectal carcinomas (mCRCs) and correlate with resistance to anti-EGFR therapy. Consequently, mCRC biomarker guidelines state RAS mutational testing should be performed when considering EGFR inhibitor treatment. However, a small subset of mCRCs are re...

Descripción completa

Detalles Bibliográficos
Autores principales: Favazza, Laura A., Parseghian, Christine M., Kaya, Cihan, Nikiforova, Marina N., Roy, Somak, Wald, Abigail I., Landau, Michael S., Proksell, Siobhan S., Dueker, Jeffrey M., Johnston, Elyse R., Brand, Randall E., Bahary, Nathan, Gorantla, Vikram C., Rhee, John C., Pingpank, James F., Choudry, Haroon A., Lee, Kenneth, Paniccia, Alessandro, Ongchin, Melanie C., Zureikat, Amer H., Bartlett, David L., Singhi, Aatur D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7483889/
https://www.ncbi.nlm.nih.gov/pubmed/32376853
http://dx.doi.org/10.1038/s41379-020-0560-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7483889/
https://www.ncbi.nlm.nih.gov/pubmed/32376853
http://dx.doi.org/10.1038/s41379-020-0560-x

Ejemplares similares